SHORT REPORT

Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma

T. M. Araújo¹,2†, A. D. Seabra¹,2†, E. M. Lima³, P. P. Assumpção¹,2, R. C. Montenegro¹,2, S. Demachki², R. M. Burbano¹,2 and A. S. Khayat¹,2*

Abstract

Background: Despite progression in treatment of gastric cancer, prognosis of patients remains poor, in part due to the low rate of diagnosis during its early stages. This paradigm implies the necessity to identify molecular biomarkers for early gastric cancer diagnosis, as well as for disease monitoring, thus contributing to the development of new therapeutic approaches. In a previous study, performed by array-Comparative Genomic Hybridization, we described for the first time in literature recurrent amplification of RTEL1 and ABCA13 genes in gastric cancer. Thus, the aim of the present study was to validate recurrent amplification of RTEL1 and ABCA13 genes and associate CNV status with clinicopathological data.

Findings: Results showed RTEL1 and ABCA13 amplification in 38% of samples. Statistical analysis demonstrated that RTEL amplification is more common in older patients and more associated with intestinal type and ABCA13 amplification increases the risk of lymph node metastasis and is more common in men. Co-amplification of these genes showed a significant association with advanced staging.

Conclusions: aCGH is a very useful tool for investigating novel genes associated with carcinogenesis and RTEL1 amplification may be important for the development of gastric cancer in older patients, besides being a probable event contributing for chromosomal instability in intestinal gastric carcinogenesis. ABCA13 amplification may have age-specific function and could be considered a useful marker for predicting lymph node metastasis in resected gastric cancer patients in early stage. Lastly, RTEL1 and ABCA13 synergistic effect may be considered as a putative marker for advanced staging in gastric cancer patients.

Keywords: Gastric cancer, aCGH, RTEL1, ABCA13, Biomarkers

Background

Gastric cancer is the fifth most frequent type of cancer and the third cause of cancer mortality worldwide [1].

The estimate for Brazil (2016 and 2017) indicates the occurrence of about 600,000 new cases of cancer. Except for non-melanoma skin cancer (approximately 180,000 new cases), there will be about 420,000 new cases of cancer. Among all different types of cancer that affect humans, gastric cancer, excluding non-melanoma skin cancer, ranks fourth as the most frequent tumor type in men and fifth in women [2]. In the Northern Brazil, excluding non-melanoma skin cancer, gastric cancer is the second most frequent cancer among men and the fourth among women [2].

The incidence rate of gastric cancer have decreased overall in recent years, however, it remains the leading cause of cancer-related mortality in developing countries [3]. Despite progression in treatment of advanced gastric
cancer, the prognosis of gastric cancer patients remains poor, in part due to the low rate of diagnosis during its early stages [4]. This paradigm implies the necessity to search and identify molecular biomarkers for early gastric cancer diagnosis, as well as for disease monitoring, thus contributing to the development of new therapeutic approaches [5].

With regard to gastric cancer treatment, with the exception of trastuzumab (therapy based on the overexpression of HER2 protein and/or the amplification of its gene ERBB2), chemotherapy of localized and advanced gastric cancer still does not consider genotypic tumor characteristics. This implies that part of the patients, if not the majority, receives medical treatment with suboptimal or even lacking efficacy [6, 7].

Recently, numerous studies have investigated the molecular basis of gastric cancer involving the alteration of pathogenesis, including the mechanisms of invasion and metastasis. With the development of modern technologies, various novel biomarkers had been identified that appear to possess diagnostic and prognostic value [4]. Among the types of biomarkers, copy number variation (CNV) in key genes has been found in gastric cancer [8–10].

In a previous study, preformed by array-Comparative Genomic Hybridization (aCGH), we observed many genomic alterations in 22 patients and described for the first time in literature the recurrent amplification of RTEL1 (Regulator of Telomere Length 1) gene, located on 20q13.33 (OMIM: 608833), and ABCA13 (ATP-Binding Cassette, Sub-Family A, Member 13) gene, located on 7p12.3 (OMIM: 607807), in gastric adenocarcinoma, with a frequency of 50 and 23 %, respectively [11].

RTEL1 is an essential helicase that has been demonstrated to be required for the maintenance of telomere length and genomic stability. Thus, RTEL1 dysfunction is dramatically mutagenic and plays an important role in tumor initiation and progression [12, 13].

ABCA13 gene is a member of ABC (ATP-binding cassette) family of transporters that plays a crucial role in the development of resistance by the efflux of anticancer agents outside of cancer cells [14]. Recently, several studies have associated overexpression of ABCA13 with poor prognosis of cancer [15, 16].

Therefore, the aim of the present study was to validate the recurrent amplification of RTEL1 and ABCA13 genes observed previously by aCGH and associate CNV status with clinicopathological data of patients.

It is noteworthy to mention that we have chosen RTEL1 gene due to high frequency of its amplification in gastric adenocarcinoma samples observed by aCGH. On the other hand, ABCA13 was chosen due to its significant association with serosal extravasation. For both genes, we have also taken into account the agreement of results with data present in literature.

CNV analysis demonstrated a significant association between gene amplification and co-amplification with clinicopathological data of patients with gastric adenocarcinoma.

Results
RTEL1 gene amplification was observed in 38 % of samples (Fig. 1). Statistical analysis showed that this amplification is 2.6 times more common in patients older than 50 years ($p = 0.045; 95 \% CI = 1.011–5.128$) and 2.3 times more associated with intestinal type ($p = 0.034; 95 \% CI = 1.057–6.3$) (Table 1).

ABCA13 gene amplification was also observed in 38 % of samples (Fig. 2). Statistical analysis showed that ABCA13 amplification increases 3 times the risk of lymph node metastasis ($p = 0.033; 95 \% CI = 1.057–9.018$). Additionally, this amplification is 4 times more common in men ($p = 0.003; 95 \% CI = 1.526–9.851$) and demonstrated an inconclusive association with intestinal type ($p = 0.079$) (Table 1).

Synergistic effect of these two amplifications was also evaluated. The results showed that RTEL1 and ABCA13 amplification in the same patient was 3 times more associated with advanced stage (III and IV) ($p = 0.05; 95 \% CI = 0.958–10.037$) (Table 1).

Subcategorization of samples into intestinal and diffuse types did not result in any significant clinicopathological association.

It is important to note that 51 % (23/45) and 21 % (10/47) of ABCA13 and RTEL1 amplifications, respectively, were high-level amplifications ($\geq 5$ copies), but subdivision of samples into high-level amplifications and other amplifications (3 and 4 copies) or high-level amplifications and all other (1, 2, 3 and 4 copies) did not result in any significant clinicopathological association.

Regarding oral squamous cell carcinoma, we observed 30 and 25 % of RTEL1 and ABCA13 amplification, respectively, but the presence of amplification was not statistically associated with clinicopathological data of patients.

Discussion
High amplification frequencies observed in the present study corroborate with the previous study performed by aCGH, indicating that this technique is useful to investigate CNV and find novel genes associated with diseases, even with a low number of cases.

The statistical association of ABCA13 with serosal extravasation [11] was not confirmed by real time PCR and new significant associations were observed, including for RTEL1 gene. This discrepancy is probably due to differences in sample size of each investigation.

The region 20q, where RTEL1 gene is located, is amplified in several types of cancer [17–19], but we were the first group to describe RTEL1 amplification in gastric cancer [11].
Rtel1 is an essential helicase for telomere maintenance and the regulation of homologous recombination (HR) [12]. HR is one of the major pathways to maintain genomic stability and is involved in the repair of complex DNA damage, DSBs, interstrand crosslinks and DNA gaps. Thus, upregulated Rtel1 function might prevent HR when it is needed as a legitimate means for repair, leading to malfunction of repair system [20].

Another hypothesis is that the excessive activity of Rtel1 would increase Rtel1 helicase activity, leading to disengaging of T-loop structure and, consequently, to telomere deprotection, which may result in end-to-end fusions and exonucleolytic attack [13, 21].

Several observations suggested a possible role for RTEL1 during DNA replication. Mouse cells deficient for RTEL1 exhibit reduced proliferative capacity, and worms and mammalian cells lacking RTEL1 are particularly sensitive to DNA damaging agents that hinder DNA replication, such as inter-strand crosslinking agents [13, 21].

Wu et al. [12] showed that increased expression of Rtel1 in mouse hepatocytes induced the development of liver tumors. This finding is consistent with human genetic data that showed that amplification of RTEL1 genomic locus is not only a common genetic alteration in human hepatocellular carcinoma, but also closely associated with its malignancy and progression [23–27].

In this study, we found for the first time recurrent RTEL1 amplification statistically associated with advanced age and intestinal type of gastric adenocarcinoma. Thus, we suggest that amplification of RTEL1 may have age-specific function and an important role in adenocarcinoma of intestinal type, which corroborates with the hypothesis that these two histological types have different genetic pathways [28, 29].

Consistent with these results, El-Rifai et al. [30] and Kokkola et al. [31] found a significant association between 20q amplification and intestinal type of gastric cancer. Interestingly, a molecular classification of gastric cancer, proposed by Cancer Genome Atlas Research Network [32], categorized intestinal gastric cancer as correlated with chromosomal instability. Thus, RTEL1 may be a key gene of 20q region, since its upregulation triggers chromosomal instability [13, 21].

Noteworthy, we observed that the frequency of RTEL1 amplification is almost equal in all stages of cancer (I-41 %, II-30 %, III-44 % and IV-44 %), corroborating with the hypothesis proposed by Tabach et al. [33] that amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer.

The human ABC transporters are encoded by a large transporter gene superfamily, which is composed of 49 members grouped into seven subfamilies (A–G) according to the sequence homology. ABC proteins facilitate translocation of heterogeneous substrates including metabolic products, lipids and sterols, peptides and proteins, saccharides, amino acids and drugs across the cell membrane. To transport these substrates across extracellular and intracellular membranes against a concentration gradient, ABCs use energy acquired by the hydrolysis of ATP [34].

![Copy number bar plot of RTEL1 gene showing high frequency of amplification in gastric adenocarcinoma samples](image)
ABCA13 is a member of ABC gene subfamily A (ABCA) that plays a crucial role in the development of resistance by the efflux of anticancer agents outside of cancer cells [14] and overexpression of one or more membrane-bound ATP-binding cassette (ABC) transporters has been associated with such mechanism of drug resistance [35].

There are few studies in literature regarding the role of ABCA13 in cancer, but they demonstrate a positive association between ABCA13 upregulation and unfavorable outcomes.

Upregulation of ABCA12, ABCA13, ABCB6, ABCC1, ABCC2 and ABCE1 genes was found by Hlavata et al. [14] in colorectal cancer samples when compared to normal tissues and Nymoen et al. [15] observed that ABCA13 mRNA overexpression was significantly related to shorter overall survival in metastatic ovarian serous carcinoma.

Importantly, Hlaváč et al. [16] stated that ABCA13, ABCB3 and ABCC1 levels were significantly higher in patients with grade 3 than in patients with grade 1 or 2 of breast carcinoma, suggesting that overexpression of these genes may be associated with poor prognosis.

In the present study, we found for the first time recurrent amplification of ABCA13 statistically associated with lymph node metastasis in gastric carcinogenesis. Therefore, we suggest that amplification of ABCA13 gene has an important role in development of lymph node metastasis, which is associated with poor outcomes [36].

Moreover, we observed a significant association between ABCA13 amplification and male gender. In this regard, it is important to note that ABC transporters can move substrates in (influx) or out (efflux) of cells, such as inorganic anions, metal ions and a large number of hydrophobic compounds and metabolites across the plasma membrane [37], which may include substances that could be harmful to health. Since men are more exposed to carcinogens than woman [38–43], the influx of carcinogenic substances by ABCA13 channel could

| Gender | ABCA13 CNV | p-value | RTEL1 CNV | p-value | RTEL1 and ABCA13 amplification | p-value |
|--------|------------|---------|-----------|---------|-------------------------------|---------|
| Male   | ≥3 copies  | 0.987   | Others    | 0.003*  | 17                            | 61      | 0.031* |
| Female |            |         |           |         |                               |         |

Table 1 Clinicopathological data of patients with and without RTEL1 and ABCA13 amplification

M male, F female, pN lymph node metastasis status, N0 without lymph node metastasis, N1 or more metastasis in one or more lymph nodes, pT extent of the primary tumor, T1–T3 without serosal extravasation, T4 with serosal extravasation, pM distant metastasis status, M1 with distant metastasis, M0 without distant metastasis. *Significant difference between groups with and without amplification, p ≤ 0.05, Chi-square test
explain the high frequency of amplification of this gene in male gender related to gastric cancer.

**Conclusion**

aCGH is a very useful tool for investigating novel genes associated with carcinogenesis. Through this technique, we were able to identify recurrent amplification of RTEL1 and ABCA13 and this observation was validated by real-time PCR for copy number analysis on a larger number of samples and in other type of cancer, demonstrating that these genes may have important roles in the carcinogenesis process. Thus, RTEL1 amplification may be important for the development of gastric cancer in older patients, besides being a probable event contributing for chromosomal instability in intestinal gastric carcinogenesis. Moreover, ABCA13 amplification may have age-specific function and could be considered a useful marker for predicting lymph node metastasis in resected gastric cancer patients in early stage. Lastly, RTEL1 and ABCA13 synergistic effect may be considered as a putative marker for advanced staging in gastric cancer patients.

**Methods**

**Samples**

We analyzed gastric adenocarcinoma samples obtained from primary gastric tumors of patients from João de Barros Barreto University Hospital (HUJBB), located in Pará State, Brazil.

All samples were obtained before administration of chemical treatments or radiotherapy. This study was approved by HUJBB ethics committee (CAAE: 42999115.7.0000.5634) and all individuals signed a Consent Form allowing the use of biological samples and clinical data.

For RTEL1 copy number investigation we used 125 fresh frozen samples (Table 1), 68 % from male and 32 % from female patients, with a mean age of 59 years (±13). Regarding tumor site, 80 % were obtained from tumors located outside from cardia region and 20 % of tumors located in the cardia region. Of the total of samples, 57 % were collected from patients with advanced stage (III and IV) and 43 % from patients with early stage (I and II), 66 % of tumors belonging to the intestinal type and 34 % to the diffuse type of Laurén. Also with respect to staging, it was observed that 23 % of patients presented serosal extravasation (T4), 76 % presented lymph node metastasis and 52 % presented distant metastasis. For ABCA13 copy number investigation we used 117 fresh frozen samples (Table 1), because eight reactions were unsuccessful.

Additionally, we evaluated CNV status of these genes in 47 oral squamous cell carcinoma samples, in an attempt to investigate if the frequency of RTEL1 and ABCA13 amplification is also high in other type of neoplasia. Sample composition was 64 % male and 36 % female patients, with a mean age of 61 years (±13). Regarding tumor site, 80 % were obtained from tumors located in tongue or floor of mouth. Of the total of samples, 56 % were collected from patients with advanced stage (III and IV) and 44 % from patients with early stage (I and II).

**Histopathology**

Tumor samples were included only if at least 80 % of the sample consisted of cancer cells. Histopathological
data, such as histological subtype, degree of differentiation, depth of invasion, lymph node involvement and distant metastases were taken from pathology reports of the Department of Pathology of HUJB. The histopathological analysis of tumor fragments was performed according to Laurén's classification [44].

Quantitative analysis of copy number variants based on real-time PCR
Genomic DNA extraction was carried out using Gentra Puregene Kit (Qiagen, Germantown, MD, USA), according to the manufacturer’s instructions. After extraction, we evaluated quantity and quality of each sample using Nanodrop 1000 Spectrophotometer (NanoDrop Technologies, Houston, TX, USA). The volume for each sample was adjusted accordingly to achieve 10 ng/μl using nuclease free water.

We performed TaqMan Copy Number Assay (Applied Biosystems, Foster City, CA). Briefly, 1 μl of 10 ng DNA was added to 5 μl of TaqMan Genotyping Master Mix (Applied Biosystems, Foster City, CA), with 0.5 μl of RTEL1 or ABCA13 probe and 3 μl of water. We measured copy number gain using the following profile: denaturation at 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. We determined relative quantification using the 7500 Real-time PCR system (Applied Biosystems, Foster City, CA) in quadruplicate. RNaseP (Applied Biosystems, Foster City, CA) was used as a control. After amplification, we imported the experiment results containing threshold-cycle values for the copy number and reference assay into the CopyCaller Software (Applied Biosystems, Foster City, CA) for post-PCR data analysis as previously described by Graziano et al. [45].

Statistics
Statistical analysis for comparisons of categorical variables between groups were done by means of Chi-square test and were performed using PASW Statistics program. Odds Ratio (OR) and Confidence Interval (CI = 95 %) were also calculated. A two-tailed probability value 0.05 was considered to be statistically significant.

Acknowledgements
We acknowledge Federal University of Pará (PROPESP and Fadesp) for technical support and National Council of Technological and Scientific Development and Coordination for Enhancement of Higher Education Personnel for financial and fellowship support.

Funding
National Council of Technological and Scientific Development (CNPq), grant nº 460185/2014-4, funded Copy Number Variation assays. Design of the study, preparation of the manuscript and collection and interpretation of data were not funded.

Availability of data and materials
The data will not be shared because some analyses of RTEL1 and ABCA13 genes were carried out together with other data that have not yet been published.

Authors’ contributions
TA and AS performed the experiments. EL participated in the design of the study and performed the statistical analysis. AK, RM and RB conceived of the study, and participated in its design and coordination and helped to draft the manuscript. PA was responsible for the surgeries. SD was responsible for histopathological analysis. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Ethics approval and consent to participate
João de Barros Barreto University Hospital ethics committee approved this study (CAAE: 42999115.7.0000.5634). The patients consent to participate to this study by signing a Consent Form allowing the use of biological samples and clinical data. Moreover, we have obtained consent from the patients to publish and to report individual data.

Author details
1 Human Cytogenetics Laboratory, Federal University of Pará, Belém 66075-110, Pará, Brazil. 2 Oncology Research Center, Federal University of Pará, Belém 66073-000, Pará, Brazil. 3 Molecular Biology Department, Federal University of Paraíba, João Pessoa 58051-900, Paraíba, Brazil.

Received: 11 April 2016 Accepted: 23 June 2016
Published online: 29 June 2016

References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed 25 mar 2016.
2. INCA - Instituto Nacional do Câncer. Estimativa 2016/2017- Incidência de câncer no Brasil. http://www.inca.gov.br. Accessed 4 mar 2016.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011. doi:10.3322/caac.20107.
4. Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: progression in early diagnosis and prognosis (Review). Oncol Lett. 2015;9(6):1502–8.
5. Wu HH, Lin WC, Tsai KW. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med. 2014. doi:10.1017/erm.2013.16.
6. Warneke VS, Behrens HM, Haag J, Balschun K, Böger C, Becker T, Ebert MP, Lordick F, Röcken C. Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol. 2013. doi:10.1097/PDM.0b013e318284188e.
7. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Oumuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.
8. Buffart TE, Carvalho B, Mons T, Reis RM, Moutinho C, Silva P, van Grieken NC, Vieith M, Stolte M, van de Velde CJ, Schrock E, Matthaei A, Ylstra B, Carneiro F, Meijer GA. DNA copy number profiles of gastric cancer precursor lesions. BMC Genomics. 2007;8:345.
9. Kang JU, Kang JJ, Kwon KC, Park JW, Jeong TE, Noh SM, Koo SH. Genetic alterations in primary gastric carcinomas correlated with clinicopathological variables by array comparative genomic hybridization. J Korean Med Sci. 2006;21:4.

10. Weiss MW, Kuipers EJ, Postma C, Snojders AM, Pinkel D, Meuwissen SG, Albertson DG, Meijer GA. Genetic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol. 2004;26(5–6):307–17.

11. Seabra AD, Araújo TM, Mello Junior FA, Di Felipe Ávila Alcântara D, De Barros AP, De Assumpção PP, Montenegro RC, Guimarães AC, Demachki S, Burbano RW, Khayat AS. High-density array comparative genomic hybridization detects novel copy number alterations in gastric adenocarcinoma. Anticancer Res. 2014;34(11):6405–15.

12. Wu X, Sandhu S, Nabi Z, Ding H. Generation of a mouse model for studying RTEL1: an essential helicase-like protein. Cell. 2004;117(7):873–84.

13. Barber LJ, Youlds JL, Ward JD, McIvoruth MJ, O’Neill NJ, Petalcorin MI, Martin JS, Collis SJ, Cantor SB, Auclair M, Tissenbaum H, West SC, Rose AM, Boulton SJ. RTEL1 maintains genomic stability by suppressing homologous recombination. Cell. 2008. doi:10.1016/j.cell.2008.08.016.

14. Hlaváčová V, Brynychová V, Václavíková R, Ehrlichová M, Vrána D, Pecha V. Genomic hybridization analysis relationship to disease stage, tumor size, and cirrhosis. Am J Pathol. 1999. doi:10.1016/S0002-9440(10)65248-0.

15. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004;15:327–49.

16. Yashiro W, Yokozaiki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E. Genetic and epigenetic alterations in multiple carcinogenesis of the stomach. J Gastroenterol. 2000;35 Suppl 1211–5.

17. El-Rifaí W, Harper JC, Cummings OW, Hytinen ER, Frierson Jr HF, Knuttila S, Powell SM. Consistent genetic alterations in xenografts of proximal stomach and gastro-esophageal junction adenocarcinomas. Cancer Res. 1998;58(1):34–7.

18. Kolkka A, Monri O, Puolakkainen P, Lanenndey ML, Victorzon M, Nordling S, Haapainen R, Kivlaaiko E, Krustulic S. 17q12–21 amplification, a novel recurrent genetic change in intestinal type of gastric carcinoma: a comparative genomic hybridization study. Genes Chromosomes Cancer. 1999;20(1):38–43.

19. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014. doi:10.1038/ nature13480.

20. Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, Hovland R, Ke XS, Oyan AM, Kalland KH, Rotter V, Domyan E. Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS One. 2011. doi:10.1371/journal.pone.0014632.

21. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992;6:87–113.

22. Sakkas G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34.

23. Ding JY, Liang H. Clinical significance of lymph node metastasis in gastric cancer. World J Gastroenterol. 2014. doi:10.3748/wjg.v20.i14.3967.

24. Gastrointestinal E. Multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34.

25. Gastrointestinal E. Multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34.

26. Laurén P. The two histological main types of gastric carcinoma: diffuse and intestinal type. Acta Pathol Microbiol Scand. 1965;64:31–6.

27. Emidio S, Ruffini R, Tocchetti D, Trinchieri G, Di Giongo G, Di Marzio P, Di Girolamo A, Cavazzini S, Ruggieri S, Bottoni E. Gender-related differences in response to mutagens and carcinogens. Mutat Res. 2010. doi:10.1016/j.mrmut.2009.02.006.

28. Kirsch-Volders M, Bonassi S, Hercog Z, Hirvonen A, Phillips DH. Gender-related differences in response to mutagens and carcinogens. Mutat Res. 2010. doi:10.1016/j.mrmut.2009.02.006.

29. Saghier AA, Kabanja JH, Afreen S, Sagar M. Gastric cancer: environmental risk factors, treatment and prevention. J Carcinogene Mutagene. 2013. doi:10.1007/s11248-011-9586-7.

30. Kokkola A, Monri O, Puolakkainen P, Larramendy ML, Victorzon M, Nordling S, Haapainen R, Kivlaaiko E, Krustulic S. 17q12–21 amplification, a novel recurrent genetic change in intestinal type of gastric carcinoma: a comparative genomic hybridization study. Genes Chromosomes Cancer. 1999;20(1):38–43.

31. Kokkola A, Monri O, Puolakkainen P, Larramendy ML, Victorzon M, Nordling S, Haapainen R, Kivlaaiko E, Krustulic S. 17q12–21 amplification, a novel recurrent genetic change in intestinal type of gastric carcinoma: a comparative genomic hybridization study. Genes Chromosomes Cancer. 1999;20(1):38–43.

32. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014. doi:10.1038/ nature13480.